Carbimazole-induced agranulocytosis: A case report

Bouizammarne, Ilham; Rafi, Sana; El, Mghari Ghizlane; El, Ansari Nawal

doi:10.1530/endoabs.63.p802

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may take four to eight weeks for symptoms to completely resolve, and typical maintenance dose ranges from 5 to 30 mg/day [1]. Patients on higher doses of carbimazole (> 30 mg/day) for more than two months and aged > 40 years are at risk of developing agranulocytosis [1,2]. The incidence of this carbimazole-induced agranulocytosis has been reported to range from 0.3% to 0.6% and is associated with a very high mortality rate of up to 21.5% [3,4].…”

Section: Introductionmentioning

confidence: 99%

Carbimazole-Induced Agranulocytosis in a Previously Stable Patient: A Case Report and Literature Review

Khan¹,

Afifi²,

Muhammad³

et al. 2022

Cureus

View full text Add to dashboard Cite

This article has been corrected at the request of the author due to presence of an error in the Discussion section which was noticed by a reader. The second sentence of the first paragraph in the Discussion section has been corrected as the original version incorrectly referred to "side effects", when in reality they are "clinical features".Original (incorrect): The common side effects of carbimazole include fever (92%), sore throat (85%), painful mouth ulcer (15%), ulcer (8%), and reduced immune response making individuals prone to infections [3].Corrected: The common clinical features of carbimazole induced agranulocytosis include fever (92%), sore throat (85%), painful mouth ulcer (15%), ulcer (8%), and reduced immune response making individuals prone to infections [3].

show abstract